Proteomics

Dataset Information

0

LC-MSMS of the MHC-I immunopeptidome of AML cell lines


ABSTRACT: The hypomethylating agent 5-azacytidine (AZA) is the first-line induction therapy for AML patients unsuitable for intensive chemotherapy. The anti-tumor effect of AZA results in part from T-cell cytotoxic responses against MHC-I-associated peptides (MAPs) deriving from hypermethylated genomic regions such as cancer-testis antigens (CTAs), or endogenous retroelements (EREs). However, clear evidence supporting higher ERE MAPs presentation after AZA treatment in AML is lacking. Therefore, we examined the immunopeptidome of four AML cell lines treated with AZA through a proteogenomic approach to validate this hypothesis.

INSTRUMENT(S): Orbitrap Exploris 480

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Blood Cell

DISEASE(S): Acute Myeloid Leukemia

SUBMITTER: Courcelles Mathieu  

LAB HEAD: Pierre Thibault

PROVIDER: PXD038663 | Pride | 2024-04-17

REPOSITORIES: pride

Dataset's files

Source:
Action DRS
MOLM-13_Aza_TMT_110321_rep1.mgf Mgf
MOLM-13_Aza_TMT_110321_rep1.raw Raw
MOLM-13_Aza_TMT_110321_rep2.mgf Mgf
MOLM-13_Aza_TMT_110321_rep2.raw Raw
MOLM-13_Aza_TMT_110321_rep3.mgf Mgf
Items per page:
1 - 5 of 70

Similar Datasets

2024-04-17 | PXD046853 | Pride
2022-08-22 | PXD026702 | Pride
2020-05-26 | PXD018124 | Pride
2014-07-29 | E-GEOD-59808 | biostudies-arrayexpress
2021-08-04 | E-MTAB-10512 | biostudies-arrayexpress
2018-10-07 | MSV000083006 | MassIVE
2016-10-25 | E-GEOD-78830 | biostudies-arrayexpress
2019-11-11 | PXD007237 | Pride
2016-10-25 | E-GEOD-78827 | biostudies-arrayexpress
2020-11-16 | PXD017918 | Pride